Alice Zhang's 'all-in-human' AI and genomics upstart scores a $98M Series B

Paul Schloesser

Associate Editor

Just a few months after California AI and genomics player Verge Genomics partnered with Eli Lilly in a $700 million-plus biobucks deal for 4 neurological programs, the biotech has finished raising its next financing round — netting $98 million in equity funding with Lilly jumping on board as a new investor.

The South San Francisco-based, neuroscience-focused company announced the completion of the Series B this morning, which was led by BlackRock-managed funds and supported by some new big-name investors such as Eli Lilly, Merck’s Global Health Innovation Fund and Vulcan Capital. Some existing investors joined in as well, including ALS Investment Fund and Tao Capital Partners.

NewsRob Maguire